Article thumbnail

Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study

By Gianpiero Fasola, Marianna Aita, Luisa Marini, Alessandro Follador, Marina Tosolini, Laura Mattioni, Mauro Mansutti, Andrea Piga, Silvio Brusaferro and Giuseppe Aprile
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. 84470.1172743348645ce4c.pdf?id=111.81951.1172658490314] Pre-publication history The pre-publication history for this paper can be accessed here:
  2. (2007). and the Value of Life: Whose Justice? Which Rationality? J Clin Oncol
  3. (2000). Browning RA: Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg
  4. (2007). Cost of Cancer Care: Issues and Implications.
  5. (2005). Edition Montvale:Thomson PDR;
  6. (2003). End points and United States Food and Drug Administration approval of oncology drugs.
  7. (2006). Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm
  8. (1998). False hopes: overcoming the obstacles to a sustainable, affordable medicine
  9. (2007). Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference. Oncologist
  10. (1996). Fliche E, Bressolle F: Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator.
  11. (2007). Gel-Moreno B: Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer. Clin Colorectal Cancer
  12. (2004). Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer
  13. Insights. World Markets [http://
  14. Italian Medicines Agency (AIFA). Official hospital drug prices [ wscs_render_attachment_by_id/
  15. (2004). Italian Trials in Medical Oncology (I.T.M.O.) Group: Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer
  16. (2006). Managing oncology costs.
  17. (1994). Mendelson DN: Eliminating waste and inefficiency can do little to contain costs. Health Aff (Millwood)
  18. (2006). PJ: Do oncologists believe new cancer drugs offer good value? Oncologist
  19. (1992). Reducing waste of intravenous solutions.
  20. (2005). Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
  21. (2004). Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol
  22. (2005). What is targeted therapy?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.